Disease · MONDO_0021042
Comparisons in its trials19
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 19 of 19
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Vorasidenib vs Matching Placebo: Objective Response (OR) as Assessed by the Blinded Independent Review Committee (BIRC) | 18 of 168 | 4 of 163 | 331 | NCT04164901 | Trial comparisons |
| Vorasidenib vs Matching Placebo: Complete Response (CR) and Partial Response (PR) by BIRC | 2 of 168 | 0 of 163 | 331 | NCT04164901 | Trial comparisons |
| Vorasidenib vs Matching Placebo: deaths from any cause | 0 of 167 | 0 of 163 | 330 | NCT04164901 | Trial comparisons |
| Vorasidenib vs Matching Placebo: serious adverse events | 11 of 167 | 8 of 163 | 330 | NCT04164901 | Trial comparisons |
| Lerapolturev vs Lerapolturev + Lomustine: Number of Participants With Objective Radiographic Response | 5 of 93 | 2 of 27 | 120 | NCT02986178 | Trial comparisons |
| Lerapolturev vs Lerapolturev + Lomustine: Safety of Lerapolturev | 17 of 94 | 8 of 26 | 120 | NCT02986178 | Trial comparisons |
| Naltrexone vs Placebo: serious adverse events | 12 of 54 | 17 of 56 | 110 | NCT01303835 | Trial comparisons |
| Anaplastic Glioma (AG) vs Glioblastoma Multiforme (GBM): Number of Participants With Adverse Events | 32 of 32 | 51 of 56 | 88 | NCT00271609 | Trial comparisons |
| Anaplastic Glioma (AG) vs Glioblastoma Multiforme (GBM): serious adverse events | 11 of 32 | 24 of 56 | 88 | NCT00271609 | Trial comparisons |
| Recurrent Glioblastoma vs Recurrent Non-glioblastoma CNS Tumors: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 73 of 74 | 9 of 9 | 83 | NCT05267106 | Trial comparisons |
| Recurrent Glioblastoma vs Recurrent Non-glioblastoma CNS Tumors: Number of Participants With Any ≥Grade 3 TEAE | 27 of 74 | 3 of 9 | 83 | NCT05267106 | Trial comparisons |
| Radiation Plus PPX(CT2103 vs Radiation + Temozolomide: Progression Free Survival PPX/RT Versus TMZ/RT for Patients With GBM Without Methylation | 31 of 42 | 15 of 21 | 63 | NCT01402063 | Trial comparisons |
| Radiation Plus PPX and Maintenance vs Radiation + Temozolomide and Maintenance: serious adverse events | 13 of 41 | 7 of 18 | 59 | NCT01402063 | Trial comparisons |
| Phase 1 Dose Escalation - Romidepsin vs Phase 2 Dose From Phase 1 - Romidepsin: serious adverse events | 0 of 8 | 0 of 40 | 48 | NCT00085540 | Trial comparisons |
| Nivolumab 240 mg vs Nivolumab 480 mg: deaths from any cause | 0 of 33 | 0 of 13 | 46 | NCT03557359 | Trial comparisons |
| Nivolumab 240 mg vs Nivolumab 480 mg: serious adverse events | 9 of 33 | 4 of 13 | 46 | NCT03557359 | Trial comparisons |
| Arm A vs Arm B: serious adverse events | 8 of 22 | 5 of 14 | 36 | NCT01380782 | Trial comparisons |
| Dose Escalation Part: E7016 4 mg/kg/Day + Temozolomide 150 mg/m^2 vs Dose Escalation Part: E7016 8 mg/kg/Day + Temozolomide 150 mg/m^2: deaths from any cause | 4 of 9 | 0 of 3 | 12 | NCT01127178 | Trial comparisons |
| Dose Escalation Part: E7016 4 mg/kg/Day + Temozolomide 150 mg/m^2 vs Dose Escalation Part: E7016 8 mg/kg/Day + Temozolomide 150 mg/m^2: serious adverse events | 5 of 9 | 1 of 3 | 12 | NCT01127178 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021042/comparisons